drugset
drugset / Trial / NCT05401305

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

NCT05401305 ↗

Phase 1 Completed 60 enrolled St. Petersburg Research Institute of Vaccines and Sera
RandomizedParallel-groupSingle-blindPrevention

Summary

Trial purpose is to evaluate the safety, tolerability and reactogenicity of the Vaccine for the prevention of infections caused by Haemophilus Influenzae Type b in volunteers aged 18-50.

Timeline

Start
2020-01-14
Primary completion
2020-03-30
Completion
2020-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Baby-Hib Vaccine 0.5 ml Intramuscular

Indications

haemophilus infectious disease